Stock AnalizAlto Neuroscience, Inc. ANRO
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Alto Neuroscience, Inc. (ANRO) is a healthcare company listed in the US with a market value of about $1.2B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -31%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Net income | -$63M | -$61M | -$36M |
| Free cash flow | -$52M | -$49M | -$34M |
| EPS (diluted) | $-2.19 | $-2.50 | $-9.73 |
| Net margin | — | — | — |
| ROIC | -30.3% | -32.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $38.67, 31% above the current price; targets range from $26.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-2.54 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Alto Neuroscience pay a dividend?
Not currently.
Is Alto Neuroscience a good stock to buy?
We do not give buy or sell advice. Alto Neuroscience scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.